HC Wainwright Analysts Lower Earnings Estimates for MindWalk

Key Points

• HC Wainwright lowered MindWalk’s earnings forecasts, including Q1 2027 EPS to $(0.05) from $(0.04), while maintaining a Buy rating. Its projections indicate continued losses through FY2029, with profitability not expected until FY2030.
• MindWalk recently reported a quarterly loss of $(0.06) per share, missing the $(0.05) consensus estimate, on revenue of $3.03 million. The company also reported sharply negative net margin and return on equity.
• Analyst sentiment remains mixed: the stock has a consensus “Moderate Buy” rating and $5.00 target price, but Wall Street Zen downgraded it to Sell. Shares opened at $1.36, well below their one-year high of $3.25.

MindWalk Holdings Corp. (NASDAQ:HYFT - Free Report) - Investment analysts at HC Wainwright reduced their Q1 2027 earnings estimates for MindWalk in a note issued to investors on Thursday, July 23rd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.05) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for MindWalk's current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for MindWalk's Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.17) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at $0.01 EPS.

MindWalk (NASDAQ:HYFT - Get Free Report) last posted its earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). The firm had revenue of $3.03 million during the quarter. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%.

Other equities analysts also recently issued research reports about the company. JonesTrading started coverage on MindWalk in a research report on Thursday, April 16th. They issued a "buy" rating and a $5.00 price objective for the company. Weiss Ratings restated a "sell (e+)" rating on shares of MindWalk in a report on Wednesday, July 15th. Finally, Wall Street Zen lowered MindWalk from a "hold" rating to a "sell" rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $5.00.

MindWalk Price Performance

NASDAQ HYFT opened at $1.36 on Monday. The company has a market cap of $63.53 million, a price-to-earnings ratio of -6.18 and a beta of 0.83. MindWalk has a one year low of $0.99 and a one year high of $3.25. The stock's 50 day simple moving average is $1.56. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.72 and a current ratio of 2.80.

Institutional Trading of MindWalk

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in MindWalk by 8.4% during the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company's stock worth $435,000 after buying an additional 18,600 shares in the last quarter. Jane Street Group LLC increased its stake in shares of MindWalk by 147.3% in the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company's stock valued at $293,000 after buying an additional 96,018 shares during the period. XTX Topco Ltd increased its stake in shares of MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company's stock valued at $149,000 after buying an additional 44,331 shares during the period. Bank of Montreal Can raised its position in shares of MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company's stock worth $100,000 after acquiring an additional 24,500 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in shares of MindWalk during the fourth quarter worth $91,000. Institutional investors and hedge funds own 6.70% of the company's stock.

MindWalk News Summary

Here are the key news stories impacting MindWalk this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on MindWalk and the broader brokerage view remains Moderate Buy, suggesting Wall Street still sees upside potential despite near-term losses. MindWalk Holdings Corp. NASDAQ: HYFT Given Consensus Rating of "Moderate Buy" by Brokerages
• Neutral Sentiment: MindWalk’s latest earnings call highlighted the company’s growth efforts, but the business is still posting persistent losses, keeping investor focus on the path to profitability. MindWalk Holdings Charts Growth Amid Persistent Losses
• Negative Sentiment: HC Wainwright cut earnings estimates across multiple periods, including FY2027, FY2028, FY2029, and FY2030, signaling a weaker profit outlook and pressuring the stock. Brokers Issue Forecasts for MindWalk FY2031 Earnings
• Negative Sentiment: Another analyst report from Wall Street Zen lowered its rating on HYFT, adding to concerns that recent expectations may be too optimistic. MindWalk NASDAQ: HYFT Stock Rating Lowered by Wall Street Zen

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.